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Abstract
Phase-change contrast agents (PCCAs), which normally consist of nano/microscale droplets of
liquid perfluorocarbons (PFCs) in an encapsulating shell, can be triggered to undergo a phase
transition to the highly-echogenic gaseous state upon the input of sufficient acoustic energy. As a
result of the subsequent volumetric expansion, a number of unique applications have emerged that
are not possible with traditional ultrasound microbubble contrast agents. Although many studies
have explored the therapeutic aspects of the PCCA platform, few have examined the potential of
PCCAs for molecular imaging purposes. In this study, we demonstrate a PCCA-based platform for
molecular imaging using αvβ3-targeted nanoscale PCCAs composed of low-boiling-point PFCs.
In-vitro, nanoscale PCCAs adhered to target cells, could be activated and imaged with a clinical
ultrasound system and produced a six-fold increase in image contrast compared to non-targeted
control PCCAs and a greater than fifty-fold increase over baseline. Data suggest that low-boiling-
point nanoscale PCCAs could enable future ultrasound-based molecular imaging techniques in
both the vascular and extravascular space.
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Contrast-enhanced ultrasonography based on microbubble contrast agents (MCAs) is a
promising field with a wide range of applications for diagnostic and therapeutic purposes
(Hernot and Klibanov 2008; Qin et al. 2009; Stride and Coussios 2010; Staub et al. 2010).
By modifying the lipid, albumin, or polymer shell encapsulating typical MCAs to contain
specific, high-affinity targeting ligands, a number of preclinical studies have demonstrated
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the feasibility of using ultrasound molecular imaging (USMI) to detect cardiovascular
disease, angiogenesis of solid tumors, inflammation processes, atherosclerosis, and
thrombus (Klibanov 2006; Deshpande et al. 2009; Voigt 2009).
However, there are some fundamental limits and confounding factors involved with USMI
based on MCAs. First, the perfluorocarbon (PFC) gas-core MCAs typically have low
stability in circulation and dissolve into the surrounding media quickly. This, in combination
with passive and active clearance by the lungs and mononuclear phagocyte system, results in
a rapid elimination of contrast-providing agents over the course of several minutes (Mullin
et al. 2011). Typical USMI schemes rely on measuring accumulation of a generally low
number of targeted agents over time after a sufficient ‘wait time’ that allows for clearance of
non-targeted, circulating agents (Gessner and Dayton 2010). Second, the size of MCAs that
maximizes contrast once targeted (typically >1 µm in diameter (Streeter et al. 2010)) limits
the MCAs to flow within the vascular space after injection. As a result, they are designed
solely to target vascular diseases, such as inflammation, or intravascular markers that are
indicators of processes beyond the vascular space, such as angiogenesis resulting from solid
tumor growth (Figure 1a). Many approaches to molecular imaging and drug delivery in
other modalities have exploited the enhanced permeability and retention effect of ‘leaky’
solid tumor vasculature to gradually accumulate particles on the order of 100 nm in the
extravascular space via passive diffusion (Mulder et al. 2006). Though efforts have been
made to generate targeted MCAs in sizes small enough to potentially diffuse beyond the
vascular space and be registered by ultrasound imaging (Wang et al. 2011a), the reduced
scattering cross-section of these particles (Quaia 2005) in combination with a resonance
frequency much greater than those used for human diagnostic imaging (Sassaroli and
Hynynen 2005) will significantly decrease the contrast provided. Furthermore, microbubbles
with sizes on the order of 100s of nanometers are prone to collapse due to increasing
Laplace pressures, which makes stabilizing such small bubbles challenging.
Phase-Change Contrast Agents
Several alternatives to MCAs exist for USMI. Contrast agents based on liquid
perfluorocarbon nanodroplets have been proposed because as they exhibit some
echogenicity (though inherently less than microbubbles) and are more stable in circulation
than MCAs (Mattrey 1989; Behan et al. 1993; Hall et al. 2000; Marsh et al. 2002; Lanza et
al. 2010). The more recent concept of acoustically activated phase-change contrast agents
(PCCAs) has gained attention for diagnostic and therapeutic ultrasound (Kripfgans et al.
2000; Sheeran and Dayton 2012a). These agents are typically composed of PFCs that have
boiling points close to body temperature, such as dodecafluoropentane (boiling point, 28–
30°C) and perfluorohexane (boiling point, 58–60°C) (Kripfgans et al. 2000; Giesecke and
Hynynen 2003; Fabiilli et al. 2009). Although they begin as liquid PFC droplets, they can be
‘tipped’ into the gaseous state by sufficient acoustic energy, or through heat-based effects.
The resulting expansion in volume leads to a gas bubble 4–10 times the original diameter by
ideal gas law predictions in combination with surface tension effects, and depending on
initial droplet size and environmental conditions (Evans et al. 2006; Sheeran et al. 2011a).
For the purposes of particles capable of extravasation, PCCAs present a unique advantage
for ultrasound, in that particles in the liquid state can be generated at sizes small enough to
extravasate, but become highly echogenic bubbles upon activation (Rapoport et al. 2009;
Sheeran et al. 2011a). While the contrast provided by activated PCCAs has been
demonstrated in several investigations (Kripfgans et al. 2000; Kripfgans et al. 2002), few
studies have explored the potential of PCCAs as diagnostic agents for USMI.
One challenge in designing diagnostic and molecular imaging PCCAs at the microscale and
nanoscale stems from the increase in surface tension effects. The Laplace pressure exerted
on the core of PFC droplets as a result of surface tension scales with the inverse of the
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particle’s radius, and thus particles at the nanoscale can experience several atmospheres of
additional pressure (Rapoport et al. 2009; Sheeran et al. 2011a). Because a compound’s
boiling point increases with increasing pressure (by the Clausius-Clapeyron relation), this
results in a significantly increased ‘effective boiling point’ for the compound, which
increases the ultrasound energy needed to vaporize the droplet. Several studies have shown
that, as a result of this effect, microscale droplets can remain stable at temperatures up to
40°C above their bulk boiling point, although they can still be vaporized with diagnostically
relevant acoustic parameters (Giesecke and Hynynen 2003; Fabiilli et al. 2009; Martz et al.
2011). Nanoscale PCCAs of the typically-used PFCs, on the other hand, may require
acoustic parameters only suitable for therapeutic purposes (Zhang and Porter 2010; Sheeran
et al. 2011a). A recent study by Wang and colleagues demonstrated active PCCA targeting
to cancer cells in vitro through aptamer-conjugated droplets of dodecafluoropentane – the
most commonly used perfluorocarbon for PCCAs (Wang et al. 2011b). As a result of the
significant pressures needed to induce phase-transition, the authors observed mechanical cell
destruction coinciding with vaporization. While this result may be a desirable result for
therapeutic/drug delivery applications, a non-invasive imaging approach should avoid the
likelihood of bioeffects.
Generating PCCAs from Low-Boiling-Point PFCs
The ability to create sub-micron PCCAs with low vaporization thresholds has been recently
demonstrated through formulation using very low-boiling-point PFCs such as
decafluorobutane (DFB, boiling point −1.1 to −2°C), octafluoropropane (boiling point
−36.7°C), and as well as mixtures of each (Sheeran et al. 2011a; Sheeran et al. 2011b;
Sheeran et al. 2012b). This is accomplished by exploiting the ‘bi-stable’ nature of the
particles created by the influence of Laplace pressure; at larger sizes the internal pressure is
much less and the particles prefer the gaseous state, whereas at very small sizes the internal
pressure is very high – hence a greatly increased ‘effective boiling point’ – and the particles
will remain stable in the liquid state well above their atmospheric pressure boiling point
(Rapoport et al. 2009; Sheeran et al. 2011a). This property has also resulted in the
development of a simple, high-yield technique of ‘microbubble condensation’ to generate
microscale and nanoscale PCCAs from compounds that are normally a gas at room
temperature (Sheeran et al. 2011b). In preliminary demonstrations, it has been observed that
this method is effective for creating DFB droplets with diameters in the 200–400 nm range,
and that the DFB droplets have significantly reduced vaporization thresholds compared to
droplets composed of more commonly used PFCs (such as perfluoropentane) as a result of
the greatly-decreased boiling point. DFB droplet samples were shown to remain stable in
distribution and concentration for periods greater than 1 hour once exposed to physiologic
temperatures (Sheeran et al. 2012b), which is promising for in vivo applications requiring
accumulation of circulating agents.
One of the primary benefits of the microbubble condensation technique is that it allows for
simple modification of droplet properties (size, composition) by altering the precursor
MCAs through well-described methods. Nanodroplets capable of USMI or gene delivery
can be generated by first preparing MCAs containing targeting ligands or gene vectors and
then condensing to the droplet form. PCCAs generated via this method have the potential to
be made in sizes small enough to extravasate into the tumor interstitium and target specific
cell markers, and then be activated to form echogenic MCAs and be registered through
ultrasound imaging (Figure 1B). Even as purely intravascular agents, PCCAs may have
benefits in reducing the ‘wait time’ needed to obtain imaging contrast. Once a sufficient
number of droplets have accumulated at the vascular site of interest, an activation pulse may
be delivered to vaporize the agents in a desired location (Figure 1C). The remaining non-
activated droplets still in circulation will have very little contrast relative to the highly
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echogenic targeted bubbles, and so information on molecular expression may be gathered
more quickly.
In this study, we explore in vitro the feasibility of using PCCAs derived from low-boiling-
point PFCs as USMI agents. We demonstrate that targeting ligands can be simply
incorporated into the encapsulating shell of the precursor microbubbles, and that the
resulting droplets successfully target cellular markers of angiogenesis (such as αvβ3).
Furthermore, the main benefit using low-boiling-point PFCs is demonstrated by activating
targeted droplets using a clinical diagnostic ultrasound machine while maintaining the
adhesion of the resultant microbubble to the cellular marker.
Methods
Microbubble Preparation
All lipid solutions consisted of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene-glycol)-2000
(DSPE-PEG2000), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
maleimide(polyethylene-glycol)-2000 (DSPE-MALPEG2000), in a 9:0.5:0.5 molar ratio,
respectively, with a total lipid concentration of 1.0 mg/mL (Avanti Polar Lipids, Alabaster,
AL). To create a particle designed to target αvβ3 integrins, a cyclic RGD peptide (Cyclo-
Arg-Gly-Asp-D-Tyr-Cys) cross-linked to DSPE-MAL-PEG2000 was included similar to
previous studies by our group (Streeter et al. 2010). Similarly, non-targeted (sham control)
particles were created using a cyclic RAD peptide (Cyclo-Arg-Ala-Asp-D-Tyr-Cys) cross-
linked to DSPE-MAL-PEG2000 that is known to not target αvβ3 integrins. The cyclic RAD
and RGD peptides were purchased from Peptides International (Louisville, KY). The
excipient solution was comprised of phosphate-buffered saline (PBS), propylene glycol, and
glycerol (16:3:1) for a total lipid concentration of 1.0 mg/mL. After adding 1.5 mL of the
resulting solution to a 3 mL glass vial, the headspace of the vial was gas-exchanged with
decafluorobutane (Fluoromed, Round Rock, TX). MCAs were formed via standard
mechanical agitation techniques using a Vialmix shaker (Bristol-Myers-Squibb, New York,
NY).
Microbubble Condensation
MCA samples were condensed using a protocol from previous studies (Sheeran et al.
2011b). Briefly, the 3 mL vials containing DFB MCAs were submerged in a CO2/
isopropanol bath, controlled to a temperature between −5°C and −10°C, and swirled gently
for 1 minute. A 30 mL syringe filled with room-air was connected to the vial using a 25 G
needle through the septum, and the plunger was depressed using a mechanical system until
headspace pressure reached approximately 5–10 psi and a change in consistency was noted
in the sample – indicating the onset of condensation. Throughout this procedure, the vial
was gently swirled and observed periodically to ensure the lipid solution did not freeze due
to the low temperatures used. After condensation, the syringe needle was removed from the
vial, leaving a slight pressure head on the solution.
Sample Sizing
Targeted and non-targeted MCA size distributions were measured using an Accusizer 780
(Particle Sizing Systems, Santa Barbara, CA) capable of measuring particles as small as 0.5
µm in diameter. Accusizer sample volumes were typically 3 µL for bubble samples.
Dynamic light scattering (Malvern Nano ZS, Malvern Instruments Ltd., Malvern,
Worcestershire, U.K.) was employed to characterize droplet distributions after condensation.
Approximately 1 to 1.5 mL of each condensed droplet sample was transferred to a cuvette
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and the size distribution of the sample measured 3 times and averaged. The Malvern Nano
ZS was capable of measuring particles as large as 6 µm in diameter.
Cell Culture
Human umbilical vein endothelial cells (HUVEC) (CC-2519) were cultured in Endothelial
Cell Basal Medium-2 (EBM-2; CC-3156) supplemented with EGM-2 SingleQuot Kit Suppl.
& Growth Factors (CC-4176) (Lonza, Walkersville, MD). HUVEC in culture have been
previously shown to overexpress the αvβ3 integrin (Dayton et al. 2004). Cells were
maintained in a humidified atmosphere containing 5% CO2 at 37 °C, and were grown in a
monolayer on nearly acoustically transparent Thermanox™ slips (Nalge Nunc International,
Rochester, NY) coated with 2% gelatin.
When cells reached 80–90% confluence they were incubated for 15 minutes with 100 µL of
the droplet solution diluted in 3 mL of media. After incubation, the cover slips were
rigorously washed with media by flushing at 3 mL syringe over the coverslip at a rate of
approximately 0.5 mL/second and then samples were placed in a metal holder. A media-
filled fluid pocket was created with a gasket and Thermanox™ cover slip opposite the glass
cover slip (Figure 2).
Microscopy
Brightfield images were obtained at two time-points: just after the cell/PCCA sample
incubation period, and just after cell exposure to ultrasound. In order to capture microscope
images after ultrasonic imaging, the fluid pocket formed by the gasket and dual
Thermanox™ slips was taken apart and the lower coverslip submerged in a 6-well plate with
3 mL of PBS. All images were captured using a 60X immersion objective (NA=1.0) with a
BX51 Microscope (Olympus, Center Valley, PA) and Metamorph Basic software
(Molecular Devices, Sunnyvale, CA).
Experimental Apparatus
Ultrasound imaging of each sample was performed with a Siemens Sequoia Imaging System
(Acuson Sequioa 512) with a 15L8 linear array transducer positioned at an angle relative to
the sample (as shown in Figure 3) to minimize specular reflections back towards the
transducer. The transducer was placed in a clamp that was mounted to a 2-D motion stage
with the ability to elevationally control the transducer position using a custom LabVIEW
(LabVIEW, National Instruments Corp., Austin, TX) program for the goal of generating
volumetric data. Samples contained in the metal holder were placed in a plastic-lined
degassed water-bath at body temperature (37°C) using acrylic stand-offs to adjust the height
relative to the transducer. The focal point of the transducer was set to the axial position of
the cell sample located on the Thermanox™ cover slip. Volumetric B-mode scans were
acquired for overlays and drawing regions of interest using the system’s compounding mode
(Freq: 14 MHz, Mechanical Index (MI): 0.1) while stepping the transducer at 0.4 mm
increments across the cover slip. The elevational beamwidth was previously determined to
be 0.8 mm (Thijssen et al. 2007, Feingold et al. 2010). Similarly, baseline volumetric
Cadence™ pulse sequencing (CPS) scans (Freq: 7 MHz, MI: 0.18, CPS Gain: −20dB) were
acquired with elevational increments of 0.4 mm stepped across the sample. To vaporize
targeted and non-targeted droplets present in the samples, the system was set to B-mode
with a MI of 1.1 and a frequency of 8 MHz while the transducer was elevationally translated
at 1 mm/s across the sample with an imaging frame rate of 30 Hz. These acoustic parameters
were chosen based on prior in vitro work demonstrating that 2–3 cycle imaging pulses (such
as those delivered by the Sequoia) with mechanical indices of 1 or higher are sufficient to
cause DFB droplet vaporization (Sheeran et al. 2011b; Sheeran et al. 2012b). After exposure
to the higher pressure, the sample was rescanned in CPS mode (Freq: 7 MHz, MI: 0.18, CPS
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Gain: −20dB) to capture the increase in contrast from the newly formed bubbles. All other
ultrasound parameters (such as gain and time-gain compensation) were kept constant
between samples.
Data Analysis
Contrast enhancement was measured using the Siemens Sequoia CPS mode where the mean
pixel intensities of the volumetric data were assumed to be proportional to the degree of
molecular biomarker expression. Regions of interest were manually drawn around the
perimeter of the cover slip boundaries in each image plane using the previously acquired B-
mode image data. With custom MATLAB (The Mathworks, Natick, MA) scripts, the
volumetric intensities for each cover slip were obtained by summing all of the pixel intensity
values for each voxel within the drawn regions of interest and dividing that value by the
total number of voxels within the volume. For each targeted (N = 6) and non-targeted (N =
6) experiment, mean volumetric intensities from pre- and post-vaporization images were
calculated to yield a final volumetric measure of αvβ3 targeting. Significance between
compared distributions was analyzed in Excel using a two-sided student’s t-test with equal
variance. The significance between the different distributions was considered at a value of p
< .05. Images were created by setting the acquired CPS intensity data to a green-scale of 0 to
256 and creating overlays of the CPS and B-mode data.
Results
In these results, we demonstrate the feasibility of using low-boiling-point PCCAs for
diagnostic USMI by comparing the in vitro contrast enhancement provided after incubating
targeted samples with αvβ3-expressing HUVECs and inducing vaporization with a clinical
diagnostic ultrasound machine.
Sample Sizing
Targeted and non-targeted samples had similar distributions in both the precursor MCA
stage and the condensed droplet stage. The originating cyclic RGD (targeted) and cyclic
RAD (non-targeted) MCA samples had mean diameters of 1.07 ± 0.78 µm and 1.09 ± 0.94
µm, respectively (Figure 3a). The condensed droplets typically formed peaks at 295 nm in
diameter with a wide distribution through the nanoscale range (Figure 3b), including the
presence of outlier microscale droplets resulting from bubbles greater than 5 µm present in
the original MCA distribution.
Ultrasonic Vaporization and Microscopy
To demonstrate the feasibility of USMI with low-boiling-point PCCAs, a total of 12 plated
HUVEC samples expressing αvβ3 were incubated with targeted (N=6) and non-targeted
(N=6) droplet samples and then imaged by a Siemens Sequoia. Activation pulses over the
coverslip length took approximately 20 seconds, and the ultrasound imaging scan was taken
within 30 seconds of the final activation pulse. After the imaging data was captured
(approximately 50 seconds), 2–3 minutes elapsed while samples were transferred to the
microscope. Both contrast-specific ultrasound CPS scans and microscopy results suggest
that very few bubbles were present prior to the activation pulse for both targeted and non-
targeted samples, indicating that any targeted particles were likely still in the condensed
liquid state (low echogenicity) after the incubation period (Figures 4a, 5a). In the
microscopy images, the presence of outlier microscale droplets could be observed in
targeted samples, although nanoscale droplets were not optically resolvable (Figure 5a).
After the HUVEC cell samples were exposed to the activation pulse (mechanical index of
1.1 at 8 MHz), samples that were incubated with targeted droplets showed the presence of
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newly-created regions of high contrast (many that maximized the CPS signal) - indicating
the presence of highly echogenic bubbles not previously there (Figure 4b). This was
confirmed by microscopy, where only slides incubated with targeted droplets showed a
significant presence of still-adherent bubbles (Figure 5b), although many bubbles became
detached and were lost in the process of dis-assembling the fluid pocket and re-submerging
the cell-bearing coverslip in the 6-well plates for microscope imaging.
Throughout the course of the tests, a small degree of non-selective droplet targeting was
observed for samples incubated with cyclic RAD droplets that resulted in ultrasound
contrast. This was also confirmed by the presence of occasional microscale droplets (before
the vaporization pulse) and MCAs (after the vaporization pulse) on these samples in
microscopy images, although a significantly smaller number than present for targeted
samples.
Ultrasound scans were taken across the cell samples at elevational increments of 0.4 mm for
a total of 41 ultrasound ‘slices’ per sample before and after exposure to the activation pulse.
Rendering the ensemble of slices in 3D allows for visualization of the volumetric data
(Figure 6) – revealing the drastic difference in contrast enhancement provided by αvβ3-
targeting droplets as well as the spatial variation in the targeting/activation across the cell
plates. As the elevational resolution of the transducer is approximately 0.8 mm at 7 MHz
(Thijssen et al. 2007, Feingold et al. 2010), each intermediate image was discarded from the
dataset to ensure no overlap in data between slices, resulting in a total of 20 volumetric
slices per sample for data analysis. Over the 6 cell samples tested for each group (targeted,
non-targeted), the ultrasound data showed a mean intensity of approximately 19.0 ± 11.8
arbitrary units for samples incubated with targeted droplets (N=6), and a mean intensity of
approximately 3.3 ± 3.9 arbitrary units for non-targeted droplets (N=6) (Figure 7). The post-
vaporization data was statistically significant over baseline for targeted samples (p=0.01),
but not for non-targeted samples (p=0.10). The baseline scans were not statistically
significant between targeted and non-targeted groups (p=0.23). Comparing the targeted to
non-targeted data shows a statistically significant (p=0.02), nearly 6-fold increase in the
mean image intensity (in dB).
Discussion
These results show proof-of-principle that PCCAs generated from low-boiling-point
perfluorocarbons can be used as effective, dynamic USMI agents with unique properties
compared to standard MCA-based USMI agents. To our knowledge, this is the first study, to
date, that demonstrates diagnostic USMI with PCCAs where vaporization pulses were
delivered from a clinical diagnostic ultrasound machine. The latter is primarily a result of
the use of very low-boiling-point perfluorocarbons that require inherently less acoustic
energy to vaporize than commonly-used PFCs such as dodecafluoropentane. In this study, a
cyclic RGD peptide was incorporated into the encapsulating shell for the purpose of
targeting cellular αvβ3 expression, although in future studies a number of alternative ligands
could be selected to target specific disease states and incorporated in a simple method as
demonstrated here.
Interestingly, the fact that the bubbles resulting from vaporized droplets remained strictly in
the plane of the cells (rather than floating to the upper coverslip and showing as points of
high contrast) strongly suggests that the encapsulating shell remained intact during
vaporization, and that a significant portion of the bubbles did not become dislodged as a
result of vaporization (Figure 4). This is further evidenced by the bubbles remaining
adherent to cells after transfer to 6-well plates for microscopy (Figure 5). Whether the agents
demonstrated here have ‘excess’ shell in the droplet state primarily as a result of the
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microbubble condensation method, or whether retention of the encapsulating shell after
vaporization is a property of all PCCA generation techniques will need to be explored in
future studies. That the resulting bubbles do not dislodge during vaporization and remain
adherent to the target sites is an important factor for PCCA-based USMI in ensuring that the
contrast-providing bubbles are viable indicators of the underlying molecular processes.
Additionally, the visible confluence of the cells did not appear to be altered by the
activation, as would be expected if the cells became mechanically disrupted or dislodged
during droplet vaporization, although more work is needed to explore whether more subtle
interactions may be occurring.
In all experiments, the cell samples incubated with targeted droplets showed consistently
higher mean pixel intensity than those incubated with non-targeted droplets. That some
amount of non-selective binding occurs is consistent with both in vitro and in vivo results
using MCA-based USMI agents (Lindner et al. 2000; Leong-Poi et al. 2003; Klibanov et al.
2006; Streeter et al. 2010; Streeter et al. 2011), and so future studies establishing the extent
to which this also occurs for PCCAs will be important. Because this study investigated the
general feasibility of using PCCAs as USMI agents, much work can be done to further
optimize parameters. As with MCAs, careful study is needed to define the proper ‘wait time’
that balances agent deposition at the target site with clearance from the mononuclear
phagocyte system and general agent instability. Additionally, the ideal ultrasound
‘activation’ signal would be one that uses the least amount of energy needed (to minimize
unwanted bioeffects), and limits each droplet to only a few high-energy vaporization pulses
(to minimize secondary effects such as coalescence, fragmentation) (Dayton et al. 1999;
Chomas et al. 2001). In this study, droplets were exposed to approximately 15–20 pulses
during the period the ultrasound transducer was translating over the sample volume.
Although many small bubbles resulting from vaporization of nano-PCCAs were present
(Figure 5b), coalescence due to repeated pulsing (Postema et al. 2004) may explain the
presence of some large bubbles that were observed in the microscope images after
vaporization (on the order of 15 – 25 µm in diameter). Though present in much smaller
quantities than bubbles on the order of 1–5 µm in diameter, these large bubbles were likely
major contributors to the total scattered ultrasound signal. It is also possible that these
bubbles were a result of the larger outlier droplets present in the polydisperse samples.
Although the diameter distribution peak was on the order of 295 nm, DLS measurements
(Figure 3) and microscopy (Figure 5a) both show presence of a small amount of droplets on
the order of 1–3 µm, which could vaporize to form bubbles on this order. In this study, the
intent was to investigate the general feasibility of a PCCA-based platform for molecular
imaging. However, refinement in the broad size distribution used here is needed depending
on whether molecular imaging is aimed at the intravascular space or extravascular space.
For extravascular USMI, targeted emulsions should ideally have droplets on the order of
100–300 nm to enable extravasation, whereas vascular targeting could be accomplished with
droplets much larger.
Conclusion
Ultrasound-based molecular imaging with phase-change contrast agents presents a
promising new set of tools for detecting both intravascular and extravascular cellular
markers. Through the microbubble condensation technique, nanoscale PCCAs with both
high stability in biological media and inherently high sensitivity to ultrasound can be
generated with a wide variety of targeting ligands to detect disease-specific markers in vitro
and in vivo. One of the most unique aspects of a PCCA-based molecular imaging approach
is that the imaging modality – ultrasound – allows for real-time spatial and temporal
specificity of the agent activation and the subsequent imaging. Our demonstration suggests
that targeted PCCAs can be designed to target cell-surface receptors. Furthermore, continued
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adhesion to the receptor following activation provides strong evidence that the avidity of
both the PCCA and the resultant microbubble to the receptor is significantly robust to allow
for selective molecular imaging to cell surface markers.
Acknowledgments
This work was supported by NIH grants no. R21EB011704 (Matsunaga) and R01EB009066 (Dayton and Borden),
and pilot study funds from UNC Chapel Hill. The authors acknowledge Professor Mark Borden at the University of
Colorado for insightful discussions regarding microbubble condensation. P.S. appreciates the generous support of
the National Science Foundation as the recipient of a graduate fellowship.
References
Behan M, O'Connell D, Mattrey R, Carney D. Perfluorooctylbromide as a contrast agent for CT and
sonography: preliminary clinical results. Am J Roentgenol. 1993; 160:399–405. [PubMed:
8424361]
Chomas JE, Dayton P, May D, Ferrara K. Threshold of fragmentation for ultrasonic contrast agents. J
Biomed Opt. 2001; 6:141–150. [PubMed: 11375723]
Dayton PA, Morgan KE, Klibanov AL, Brandenburger GH, Ferrara KW. Optical and acoustical
observations of the effects of ultrasound on contrast agents. IEEE Trans Ultrason Ferroelectr Freq
Control. 1999; 46:220–232. [PubMed: 18238417]
Dayton PA, Pearson D, Clark J, Simon S, Schumann PA, Zutshi R, Matsunaga TO, Ferrara KW.
Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular
imaging of αvβ3-expressing cells. Mol Imaging. 2004; 3:125–134. [PubMed: 15296677]
Deshpande N, Needles A, Willmann JK. Molecular ultrasound imaging: current status and future
directions. Clin Radiol. 2009; 65:567–581. [PubMed: 20541656]
Evans DR, Parsons DF, Craig VS. Physical properties of phase-change emulsions. Langmuir. 2006;
22:9538–9545. [PubMed: 17073477]
Fabiilli ML, Haworth KJ, Fakhri NH, Kripfgans OD, Carson PL, Fowlkes JB. The role of inertial
cavitation in acoustic droplet vaporization. IEEE Trans Ultrason Ferroelectr Freq Control. 2009;
56:1006–1017. [PubMed: 19473917]
Feingold S, Gessner R, Guracar IM, Dayton PA. Quantitative volumetric perfusion mapping of the
microvasculature using contrast ultrasound. Invest Radiol. 2010; 45:669–674. [PubMed: 20808232]
Gessner R, Dayton PA. Advances in molecular imaging with ultrasound. Mol Imaging. 2010; 9:117–
127. [PubMed: 20487678]
Giesecke T, Hynynen K. Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets
in vitro. Ultrasound Med Biol. 2003; 29:1359–1365. [PubMed: 14553814]
Hall CS, Lanza GM, Rose JH, Kaufmann RJ, Fuhrhop RW, Handley SH, Waters KR, Miller JG,
Wickline SA. Experimental determination of phase velocity of perfluorocarbons: applications to
targeted contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control. 2000; 47:75–84. [PubMed:
18238519]
Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv
Rev. 2008; 60:1153–1166. [PubMed: 18486268]
Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-
delivery applications. Invest Radiol. 2006; 41:354–362. [PubMed: 16481920]
Klibanov AL, Rychak JJ, Yang WC, Alikhani S, Li B, Acton S, Lindner JR, Ley K, Kaul S. Targeted
ultrasound contrast agent for molecular imaging of inflammation in high-shear flow. Contrast
Media Mol Imaging. 2006; 1:259–266. [PubMed: 17191766]
Kripfgans OD, Fowlkes JB, Miller DL, Eldevik OP, Carson PL. Acoustic droplet vaporization for
therapeutic and diagnostic applications. Ultrasound Med Biol. 2000; 26:1177–1189. [PubMed:
11053753]
Kripfgans OD, Fowlkes JB, Woydt M, Eldevik OP, Carson PL. In vivo droplet vaporization for
occlusion therapy and phase aberration correction. IEEE Trans Ultrason Ferroelectr Freq Control.
2002; 49:726–738. [PubMed: 12075966]
Sheeran et al. Page 9













Lanza G, Winter P, Caruthers S, Hughes MS, Hu G, Schmieder AH, Wickline SA. Theragnostics for
tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis. 2010; 13:189–
202. [PubMed: 20411320]
Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of
angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation. 2003;
107:455–460. [PubMed: 12551871]
Lindner JR, Song J, Xu F, Klibanov AL, Singbartl K, Ley K, Kaul S. Noninvasive ultrasound imaging
of inflammation using microbubbles targeted to activated leukocytes. Circulation. 2000;
102:2745–2750. [PubMed: 11094042]
Marsh JN, Hall CS, Scott MJ, Fuhrhop RW, Gaffney PJ, Wickline SA, Lanza GM. Improvements in
the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission
line model. IEEE Trans Ultrason Ferroelectr Freq Control. 2002; 49:29–38. [PubMed: 11833889]
Martz TM, Sheeran PS, Bardin D, Lee AP, Dayton PA. Precision Manufacture of Phase-Change
Perfluorocarbon Droplets using Microfluidics. Ultrasound Med Biol. 37(11):1952–1957.
[PubMed: 21963036]
Mattrey RF. Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging. Am J
Roentgenol. 1989; 152:247–252. [PubMed: 2643258]
Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for
contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006; 19:142–164. [PubMed:
16450332]
Mullin L, Gessner R, Kwan J, Kaya M, Borden MA, Dayton PA. Effect of anesthesia carrier gas on in
vivo circulation times of ultrasound microbubble contrast agents in rats. Contrast Media Mol
Imaging. 2011; 6:126–131. [PubMed: 21246710]
Postema M, Marmottant P, Lancee CT, Hilgenfeldt S, de Jong N. Ultrasound-induced microbubble
coalescence. Ultrasound Med Biol. 2004; 30:1337–1344. [PubMed: 15582233]
Qin S, Caskey CF, Ferrara KW. Ultrasound contrast microbubbles in imaging and therapy: physical
principles and engineering. Phys Med Biol. 2009; 54:R27–R57. [PubMed: 19229096]
Quaia, E., editor. Contrast media in ultrasonography: basic principles and clinical applications. New
York: Springer; 2005.
Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam KH. Controlled and targeted tumor
chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release. 2009;
138:268–276. [PubMed: 19477208]
Sassaroli E, Hynynen K. Resonance frequency of microbubbles in small blood vessels: a numerical
study. Phys Med Biol. 2005; 50:5293. [PubMed: 16264254]
Sheeran PS, Dayton PA. Phase-change contrast agents for imaging and therapy. Curr Pharm Des.
2012a; 18:2152–2165. [PubMed: 22352770]
Sheeran PS, Luois S, Dayton PA, Matsunaga TO. Formulation and acoustic studies of a new phase-
shift agent for diagnostic and therapeutic ultrasound. Langmuir. 2011b; 27:10412–10420.
[PubMed: 21744860]
Sheeran PS, Luois S, Mullin L, Matsunaga TO, Dayton PA. Design of ultrasonically-activatable
nanoparticles using low boiling point perfluorocarbons. Biomaterials. 2012b; 33:3262–3269.
[PubMed: 22289265]
Sheeran PS, Wong VP, Luois S, McFarland RJ, Ross WD, Feingold S, Matsunaga TO, Dayton PA.
Decafluorobutane as a phase-change contrast agent for low-energy extravascular ultrasonic
imaging. Ultrasound Med Biol. 2011a; 37:1518–1530. [PubMed: 21775049]
Staub D, Schinkel AFL, Coll B, Coli S, van der Steen AF, Reed JD, Krueger C, Thomenius KE, Adam
D, Sijbrands EJ, ten Cate FJ, Feinstein SB. Contrast-enhanced ultrasound imaging of the vasa
vasorum: from early atherosclerosis to the identification of unstable plaques. J Am Coll Cardiol
Img. 2010; 3:761–771.
Streeter JE, Gessner R, Miles I, Dayton PA. Improving sensitivity in ultrasound molecular imaging by
tailoring contrast agent size distribution: in vivo studies. Mol Imaging. 2010; 9:87–95. [PubMed:
20236606]
Sheeran et al. Page 10













Streeter JE, Gessner RC, Tsuruta J, Feingold S, Dayton PA. Assessment of molecular imaging of
angiogenesis with three-dimensional ultrasonography. Mol Imaging. 2011; 10:460–468. [PubMed:
22201537]
Stride EP, Coussios CC. Cavitation and contrast: the use of bubbles in ultrasound imaging and therapy.
Proc Inst Mech Eng H. 2010; 224:171–191. [PubMed: 20349814]
Thijssen JM, Weijers G, de Korte CL. Objective performance testing and quality assurance of medical
ultrasound equipment. Ultrasound Med Biol. 2007; 33:460–471. [PubMed: 17275983]
Voigt JU. Ultrasound molecular imaging. Methods. 2009; 48:92–97. [PubMed: 19324089]
Wang CH, Huang YF, Yeh CK. Aptamer-conjugated nanobubbles for targeted ultrasound molecular
imaging. Langmuir. 2011a; 27:6971–6976. [PubMed: 21553884]
Wang CH, Kang ST, Lee YH, Luo YL, Huang YF, Yeh CK. Aptamer-conjugated and drug-loaded
acoustic droplets for ultrasound theranosis. Biomaterials. 2011b; 33:1939–1947. [PubMed:
22142768]
Zhang P, Porter T. An in vitro study of a phase-shift nanoemulsion: a potential nucleation agent for
bubble-enhanced HIFU tumor ablation. Ultrasound Med Biol. 2010; 36:1856–1866. [PubMed:
20888685]
Sheeran et al. Page 11














A) Typical MCA approach to USMI: Circulating targeted MCAs adhere to vascular markers
and accumulate over time. Targeted MCAs remaining after the number of free-circulating
MCAs has diminished enhance local contrast over background. B) A PCCA-based approach
in which circulating PCCAs target vascular markers and are activated by a high-energy
vaporization pulse. After activation, the remaining adherent microbubbles will provide high
contrast compared to circulating liquid-state PCCAs. B) Alternatively, circulating PCCAs
may be able to extravasate via the enhanced permeability and retention effect and target
interstitial markers. Subsequent vaporization by a high-energy vaporization pulse would
activate agents, resulting in targeted, high-contrast interstitial MCAs.
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Representative sizing of A) precursor microbubbles and B) targeted and non-targeted
droplets. Note: microbubbles were measured with laser-light diffraction (Accusizer) and are
presented as count-weighted distributions, while droplets are measured with dynamic light
scattering (ZetaSizer) and are presented as intensity-weighted distributions.
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Overlays of contrast-specific CPS pixel intensity (greenscale) and traditional b-mode
(greyscale) ultrasound scans of HUVEC samples incubated with targeted PCCAs. A) Prior
to activation, no contrast-specific echogenicity is detected, suggesting PCCAs are still in the
liquid state. B) After exposure to a mechanical index of 1.1 at 8 MHz, targeted droplets
vaporize to the highly-echogenic gas state, resulting in a region of high pixel intensity along
the cell-layer only.
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Microscopy images of HUVEC cells incubated with targeted DFB droplet samples A)
before exposure to a vaporization pulse delivered from a diagnostic ultrasound machine and
B) after vaporization. Before vaporization, large outlier droplets are visible, while
nanodroplets are not optically resolvable. Post-vaporization, a high number of small bubbles
on the order of 1 – 3 µm can be seen adhering to the cell plane. Large bubbles were also
visible in some microscope images that were likely a result of vaporization of outlier
droplets, or a result of coalescence due to repeat pulsing of smaller formed bubbles.
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Overlays of contrast-specific CPS intensity (greenscale) and traditional b-mode (greyscale)
ultrasound scans: 3D-rendering of the ultrasound slices across the cell sample volume
reveals the contrast enhancement provided by targeted PCCAs after the activation pulse.
Non-targeted samples did result in a small amount of contrast enhancement, most likely as a
result of non-selective binding. Note: the small amount of contrast present at the top of each
sample is an artifact of the metal holder, not a result of the presence of echogenic bubbles.
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Volumetric mean intensity of ultrasound slices for each sample before and after the
ultrasonic activation pulse.
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